Salim Bounou

Prof. Dr. Salim Bounou

Pharmaceutical sciences, Euro-Mediterranean University of Fes, Fès, Fès-Meknès, Morocco

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
RBROMAISAA BOUDZA
ROMAISAA BOUDZA
SBSalim Bounou
Salim Bounou
Jaume Segura-GarciaJaume Segura-Garcia
Jaume Segura-Garcia
Ismaïl MOUKADIRIIsmaïl MOUKADIRI
Ismaïl MOUKADIRI
Sergi MaicasSergi Maicas
Sergi Maicas
Antimicrobial resistance represents one of the most critical global health challenges of the 21st century, urgently demanding innovative strategies for antimicrobial discovery. Traditional antibiotic development pipelines are slow, costly, and increasingly ineffective against multidrug-resistant pathogens. In this context, recent advances in artificial intelligence have emerged as transformative tools capable of accelerating antimicrobial discovery and expanding accessible chemical and biological space. This comprehensive review critically synthesizes recent progress in AI-driven approaches applied to the discovery and design of both small-molecule antibiotics and antimicrobial peptides. We examine how machine learning, deep learning, and generative models are being leveraged for virtual screening, activity prediction, mechanism-informed prioritization, and de novo antimicrobial design. Particular emphasis is placed on graph-based neural networks, attention-based and transformer architectures, and generative frameworks such as variational autoencoders and large language model-based generators. Across these approaches, AI has enabled the identification of structurally novel compounds, facilitated narrow-spectrum antimicrobial strategies, and improved interpretability in peptide prediction. However, significant challenges remain, including data scarcity and imbalance, limited experimental validation, and barriers to clinical translation. By integrating methodological advances with a critical analysis of the current limitations, this review highlights emerging trends and outlines future directions aimed at bridging the gap between in silico discovery and real-world therapeutic development.

5 March 2025 in Social Sciences & Humanities Open
Verified
Journal Article
Open access
MTMohamed Taiebine
Mohamed Taiebine
CNChakib Nejjari
Chakib Nejjari
SBSalim Bounou
Salim Bounou
IYIbtissam Youlyouz-Marfak
Ibtissam Youlyouz-Marfak
AMAbdelghafour Marfak
Abdelghafour Marfak

24 January 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
MLMélanie Langlois
Mélanie Langlois
SBSalim Bounou
Salim Bounou
MTMichel J. Tremblay
Michel J. Tremblay
BBBenoit Barbeau
Benoit Barbeau
Human T-cell leukemia virus type 1 (HTLV-1) is the causal agent of adult T-cell leukemia/lymphoma and HTLV-1-associated myelopathy/tropical spastic paraparesis. Its tropism is known to be broad in cultured cell lines, while in vivo data support a more selective transmission toward CD4+ T cells and the limited targeting of other hematopoietic cell types. An essential condition for HTLV-1 infection is cell-to-cell contact, to which both virological synapse and viral biofilm have been suggested to strongly contribute. As cell lines and animal models each present their own limitations in studying HTLV-1 replication, we have explored the use of an ex vivo model based on the secondary lymphoid tonsillar tissue. HIV-1 luciferase-expressing pseudotyped viruses bearing the HTLV-1 envelope protein at their surface were first shown to recapitulate the wide spectrum of infectivity of HTLV-1 toward various cell lines. Tonsil fragments were next exposed to pseudotyped viruses and shown to be reproducibly infected. Infection by HTLV-1 Env-pseudotyped viruses was blocked by different anti-gp46 antibodies, unlike infection by HIV-1 virions. The dose-dependent infection revealed a gradual increase in luciferase activity, which was again sensitive to anti-gp46 antibodies. Overall, these results suggest that the ex vivo tonsil model represents a reliable alternative for studying HTLV-1 replication and potentially viral latency, as well as early clonal formation.

12 February 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
IJIkram Joubair
Ikram Joubair
AEAbdellatif Errabbani
Abdellatif Errabbani
SDSoukaina Daif
Soukaina Daif
JZJesus Zueco
Jesus Zueco
SBSalim Bounou
Salim Bounou
Ismaïl MOUKADIRIIsmaïl MOUKADIRI
Ismaïl MOUKADIRI
Bluetongue (BT) is a noncontagious, arthropod-borne viral disease of domestic and wild ruminants caused by bluetongue virus (BTV), an arbovirus of the Orbivirus genus within the Sedoreoviridae family. At least 36 serotypes have been identified globally; recurrent circulation of BTV-1, -4, and -8, along with the recent emergence of BTV-3 in northern Europe, underscores a persistent incursion risk for Mediterranean herds. Key drivers include climate-driven expansion of Culicoides vector niches, windborne dispersal, animal movements, and subclinical reservoirs in cattle and goats. As no specific treatment is currently available, control of bluetongue disease still relies largely on vaccination. Live-attenuated vaccines and inactivated vaccines have reduced incidence, but important limitations persist: risk of reversion and the possibility of reassortment for LAVs; requirement for multiple doses and limited cross-protection for inactivated products; and the absence of DIVA capability for both. As an alternative, next-generation platforms are under active evaluation. Subunit formulations, often VP2 combined with VP5 and/or NS1/NS2 virus-like particles (VLPs), and viral-vectored constructs demonstrate favorable safety, strong humoral and cellular responses, inherent or engineered DIVA compatibility, and potential for rapid updating against emergent serotypes. This review synthesizes recent bluetongue activity across the Mediterranean Basin and provides a critical assessment of both existing and emerging vaccine strategies, with a focus on recommending next-generation platforms that emphasize DIVA-compliant, multiserotype, and adaptable vaccination approaches, supported by integrated surveillance and vector control in the region.

23 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
IJIkram Joubair
Ikram Joubair
Guillem Montalban-FaetGuillem Montalban-Faet
Guillem Montalban-Faet
RBRomaisaa Boudza
Romaisaa Boudza
OFOuafaa Fassi Fihri
Ouafaa Fassi Fihri
JZJesus Zueco
Jesus Zueco
Ismaïl MOUKADIRIIsmaïl MOUKADIRI
Ismaïl MOUKADIRI
Bluetongue is an economically important arboviral disease affecting domestic and wild ruminants health and well-being, caused by bluetongue virus (BTV) and transmitted by Culicoides midges. More than 30 BTV serotypes may co-circulate regionally, while current vaccines face limitations related to safety and incomplete cross-protection. Here, reverse vaccinology and immunoinformatics were used to design four serotype-specific and one multiserotype multi-epitope vaccine candidates targeting BTV-1, BTV-3, BTV-4 and BTV-8. Cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes were predicted from VP2, VP5, VP7 and NS1, and linear B-cell epitopes from VP2 and VP5. Twenty-five CTL, 24 HTL and 15 B-cell epitopes met the computational antigenicity, non-allergenicity and non-toxicity screening criteria; HTL epitopes were also predicted to induce interferon-γ. Five constructs comprising 13-25 epitopes (252-471 amino acids) were fused to bovine β-defensin 2 as a putative adjuvant. Molecular docking with bovine Toll-like receptor 4 ectodomain yielded predicted binding energies ranging from -19.6 to -10.7 kcal/mol. Molecular dynamics simulations (100 ns), immune simulation, codon optimization and in silico cloning further characterized the candidates. These computational findings support the prioritization of these constructs for experimental evaluation as potential serotype-specific and multiserotype BTV vaccine candidates.

4 September 2026 in Chemistry & Biodiversity
Verified
Journal Article
Open access
PDF file
RBROMAISAA BOUDZA
ROMAISAA BOUDZA
FEFerdaous Elandaloussi
Ferdaous Elandaloussi
KBKhalid Boujdi
Khalid Boujdi
Jaume Segura-GarciaJaume Segura-Garcia
Jaume Segura-Garcia
NBNabil EL BRAHMI
Nabil EL BRAHMI
SBSalim Bounou
Salim Bounou
Antimicrobial resistance (AMR) has severely compromised the clinical utility of classical sulfonamide antibiotics, primarily owing to the emergence of resistance‐associated dihydropteroate synthase variants. In this study, sixteen N‐(1H‐indazolyl) aryl sulfonamide hybrids were evaluated as potential DHPS inhibitors against Escherichia coli and Staphylococcus aureus using disk diffusion, broth microdilution (MIC 80 ), and minimum bactericidal concentration (MBC) assays. Active compounds were characterized by in silico ADME and toxicity profiling, with molecular docking performed against wild‐type DHPS and the sulfonamide‐resistant Sul1 variant. Antibacterial activity was species‐dependent: compound 4 showed the strongest activity against E. coli (MIC = 32 µg/mL), while compounds 11 and 16 were most potent against S. aureus (MIC = 32 µg/mL), outperforming sulfathiazole and sulfisoxazole. All hybrids showed superior docking affinities to sulfamethoxazole (SMX), with compound 11 showing the highest affinity for wild‐type DHPS (−7.79 kcal/mol); compound 4 retained favorable binding against Sul1 (−6.83 kcal/mol), suggesting potential resistance resilience. Structure–activity analysis showed antibacterial efficacy is governed by aryl sulfonyl electronic effects, steric balance at the C7 indazole position, and physicochemical properties affecting Gram‐negative membrane permeability. These findings support indazole–sulfonamide hybrids as promising scaffolds that may retain predicted binding complementarity toward the Sul1‐resistant DHPS variant, warranting validation against resistant isolates and purified DHPS enzymes.